Tumor targeting using affibody molecules: Interplay of affinity, target expression level, and binding site composition

Journal of Nuclear Medicine

Volumn 53, Issue 6, 2012, Pages 953-960

  Tolmachev, Vladimir ^a   Tran, Thuy A ^a,b   Rosik, Daniel ^c   Sjöberg, Anna ^d   Abrahmsén, Lars ^e   Orlova, Anna ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^d ALBANOVA UNIVERSITY CENTER   (Sweden)

^e Algeta ASA   (Norway)

Author keywords

Affibody molecules; Affinity; HER2; Radionuclide molecular imaging; Scaffold proteins

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAQ POLYMERASE Z DOMAIN AFFIBODY IN 111; TETRAXETAN AFFIBODY IN 111; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DESIGN; DRUG SYNTHESIS; DRUG UPTAKE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; FEMALE; INDIUM RADIOISOTOPES; ISOTOPE LABELING; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEOPLASMS, EXPERIMENTAL; RECEPTOR, ERBB-2;

EID: 84861861669     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.101527     Document Type: Article

References (35)

1. Tolmachev V, Stone-Elander S, Orlova A. Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. Lancet Oncol. 2010;11:992-1000.
2. Lappano R, Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov. 2011;10:47-60.
3. Wester HJ, Kessler H. Molecular targeting with peptides or peptide-polymer conjugates: just a question of size? J Nucl Med. 2005;46:1940-1945. (Pubitemid 46657438)
4. Skerra A. Alternative non-antibody scaffolds for molecular recognition. Curr Opin Biotechnol. 2007;18:295-304. (Pubitemid 47385180)
5. Miao Z, Levi J, Cheng Z. Protein scaffold-based molecular probes for cancer molecular imaging. Amino Acids. 2011;41:1037-1047.
6. Löfblom J, Feldwisch J, Tolmachev V, Carlsson J, Ståhl S, Frejd FY. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 2010;584:2670-2680.
7. Orlova A, Magnusson M, Eriksson TL, et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 2006;66:4339-4348.
8. Friedman M, Orlova A, Johansson E, et al. Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. J Mol Biol. 2008;376:1388-1402.
9. Li J, Lundberg E, Vernet E, Larsson B, Höidén-Guthenberg I, Gräslund T. Selection of affibody molecules to the ligand-binding site of the insulin-like growth factor-1 receptor. Biotechnol Appl Biochem. 2010;55:99-109.
10. Lindborg M, Cortez E, Höidén-Guthenberg I, et al. Engineered high-affinity affibody molecules targeting platelet-derived growth factor receptor b in vivo. J Mol Biol. 2011;407:298-315.
11. Ahlgren S, Tolmachev V. Radionuclide molecular imaging using Affibody molecules. Curr Pharm Biotechnol. 2010;11:581-589.
12. 68Ga-labeled affibody molecules. J Nucl Med. 2010;51:892-897.
13. Rudnick SI, Adams GP. Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharm. 2009;24:155-161.
14. Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther. 2009;8:2861-2871.
15. Tolmachev V, Orlova A. Influence of labelling methods on biodistribution and imaging properties of radiolabelled peptides for visualisation of molecular therapeutic targets. Curr Med Chem. 2010;17:2636-2655.
16. 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers. Cancer Biother Radiopharm. 2008;23:435-442.
17. Ahlgren S, Orlova A, Rosik D, et al. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules. Bioconjug Chem. 2008;19:235-243. (Pubitemid 351213855)
18. Tran TA, Rosik D, Abrahmsén L, et al. Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging. Eur J Nucl Med Mol Imaging. 2009;36:1864-1873.
19. Adams GP, Schier R, Marshall K, et al. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res. 1998;58:485-490. (Pubitemid 28087411)
20. Adams GP, Schier R, McCall AM, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 2001;61:4750-4755. (Pubitemid 32691886)
21. Adams GP, Tai MS, McCartney JE, et al. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res. 2006;12:1599-1605.
22. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab′)2, and Fab in tumors. Cancer Res. 1989;49:5656-5663. (Pubitemid 19256448)
23. Minner S, Jessen B, Stiedenroth L, et al. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res. 2010;16:1553-1560.
24. 3](+), and shows improved biodistribution with reduced hepatic radioactivity accumulation. Bioconjug Chem. 2010;21:2013-2022.
25. 125I. J Med Chem. 2011;54:3817-3826.
26. 111In]-labeled CHX-A″ DTPA-trastuzumab and anti-HER2 ABY-025 Affibody in prostate cancer cell lines. Experiment Ther Med. 2011;2:523-528.
27. De León-Rodríguez LM, Kovacs Z. The synthesis and chelation chemistry of DOTA-peptide conjugates. Bioconjug Chem. 2008;19:391-402. (Pubitemid 351294908)
28. Graff CP, Wittrup KD. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res. 2003;63:1288-1296. (Pubitemid 36348707)
29. Qvarnström OF, Simonsson M, Carlsson J, Tran TA. Effects of affinity on binding of HER2-targeting Affibody molecules: model experiments in breast cancer spheroids. Int J Oncol. 2011;39:353-359.
30. Eigenbrot C, Ultsch M, Dubnovitsky A, Abrahmsén L, Härd T. Structural basis for high-affinity HER2 receptor binding by an engineered protein. Proc Natl Acad Sci USA. 2010;107:15039-15044.
31. Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J Mol Biol. 1982;157:105-132.
32. Hopp TP, Woods KR. Prediction of protein antigenic determinants from amino acid sequence. Proc Natl Acad Sci USA. 1981;78:3824-3828. (Pubitemid 11060471)
33. 99mTc labeled to a peptide by 4 methods. J Nucl Med. 2001;42:1870-1877.
34. Kuntz ID, Chen K, Sharp KA, Kollman PA. The maximal affinity of ligands. Proc Natl Acad Sci USA. 1999;96:9997-10002. (Pubitemid 29422500)
35. Kobayashi H, Le N, Kim IS, et al. The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points. Cancer Res. 1999;59:422-430. (Pubitemid 29048878)